XML 192 R139.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaborative and Other Relationships - Samsung Bioepis (Details)
$ in Millions, ₩ in Billions
1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2022
USD ($)
Jan. 31, 2020
USD ($)
Nov. 30, 2018
USD ($)
Nov. 30, 2018
KRW (₩)
Aug. 31, 2017
USD ($)
May 31, 2016
USD ($)
Jan. 31, 2016
USD ($)
Dec. 31, 2013
USD ($)
Feb. 29, 2012
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
product
Dec. 31, 2021
KRW (₩)
Dec. 31, 2020
KRW (₩)
Jun. 30, 2018
May 31, 2018
Feb. 29, 2012
KRW (₩)
Collaborative arrangements and non-collaborative arrangement transactions                                      
Income (loss) from equity method investments                       $ 34.9 $ 3.3 $ (77.4)          
Income tax benefit (expense)                       52.5 992.3 $ 1,158.0          
Number of ophthalmolgy biosimilar products | product                           2          
Research and development                       2,501.2 3,990.9 $ 2,280.6          
Collaboration profit (loss) sharing                       7.2 232.9 241.6          
Revenue                       10,981.7 13,444.6 14,377.9          
Samsung Bioepis                                      
Collaborative arrangements and non-collaborative arrangement transactions                                      
Upfront and milestone payments made to collaborative partner   $ 100.0                                  
Research and development expense asset acquired                           63.0          
Prepaid research and discovery services                           37.0          
Accrued milestone payment                   $ 15.0                  
Estimated additional payments upon achievement of development and commercial milestones                       $ 180.0              
Term of collaboration agreement               10 years       5 years              
Option exercise fee                       $ 60.0              
Research and development               $ 46.0                      
Expected profit share percentage                       50.00%              
Collaboration profit (loss) sharing                       $ 285.4 266.5 241.6          
Revenue                       20.7 20.9 $ 106.2          
Due from related parties                       4.1 5.1            
Due to related parties                       148.7 99.0            
Samsung Bioepis | Subsequent Event                                      
Collaborative arrangements and non-collaborative arrangement transactions                                      
Proceeds from divestiture of interest in joint venture $ 1,000.0                                    
Due from joint venture 1,300.0                                    
Estimated additional payments upon achievement of development and commercial milestones 50.0                                    
Samsung Bioepis | Payment Due At First Anniversary | Subsequent Event                                      
Collaborative arrangements and non-collaborative arrangement transactions                                      
Due from joint venture 812.5                                    
Samsung Bioepis | Payment Due At Second Anniversary | Subsequent Event                                      
Collaborative arrangements and non-collaborative arrangement transactions                                      
Due from joint venture $ 437.5                                    
Samsung Bioepis | Development Milestones                                      
Collaborative arrangements and non-collaborative arrangement transactions                                      
Additional milestone payment                     $ 15.0                
Samsung Bioepis                                      
Collaborative arrangements and non-collaborative arrangement transactions                                      
Contributions by third party                 $ 250.0                   ₩ 280.5
Joint venture ownership percentage                 85.00%                    
Investment in Samsung Bioepis                 $ 45.0     $ 599.9 620.2   ₩ 713.3 ₩ 673.8     ₩ 49.5
Ownership percentage                 15.00%     49.90%     49.90%   49.90%   15.00%
Ownership percentage before additional purchase transaction                                   5.00%  
Payments to increase investment in Samsung Bioepis     $ 676.6 ₩ 759.5                              
Total basis difference     $ 675.0                                
Net profits on investment                       $ 34.9 5.3            
Income (loss) from equity method investments                       64.6 45.3            
Amortization                       29.7 $ 40.0            
Income tax benefit (expense)                       $ 31.2              
Additional milestone payment               $ 25.0                      
Net change in acquired and in-licensed rights and patents         $ 75.0 $ 75.0 $ 75.0                        
Samsung Bioepis | Inventories                                      
Collaborative arrangements and non-collaborative arrangement transactions                                      
Equity method investment basis difference amortization period                       1 year 6 months              
Samsung Bioepis | Completed technology                                      
Collaborative arrangements and non-collaborative arrangement transactions                                      
Equity method investment basis difference amortization period                       15 years